Objective:
The article examines the objective, findings, and clinical context described in Glaucoma Neuroprotection: Still Searching for the Right Notes.
Approach:
- Nicotinamide: The presentation reviewed preclinical and early human findings on nicotinamide, an NAD precursor, and evidence from studies assessing visual function and glaucoma progression.
- GLP-1 receptor agonists: The presentation considered preclinical evidence and observational studies of glaucoma rates, alongside safety concerns and the need for randomized trials.
Key Findings:
- In animal models, nicotinamide increased NAD levels and prevented glaucomatous damage; early human studies reported functional improvements, but measures such as PhNR and individual visual-field locations are variable.
- A prospective Hong Kong trial of nicotinamide riboside found no protective effect against glaucoma progression, with potentially worse outcomes among older participants.
- High-dose nicotinamide has been associated with hepatotoxicity. Dr. Welsbie said he does not routinely recommend it while awaiting randomized-trial results, including those from the phase 3 NAMinG trial.
- Preclinical research suggests GLP-1 receptor agonists may reduce neuroinflammation. Observational studies reported lower glaucoma rates among users, but cannot establish causality or show slowed progression in established glaucoma.
- GLP-1 receptor agonists have been associated with rare nonarteritic anterior ischemic optic neuropathy (NAION). Dr. Welsbie said randomized trials are needed to assess glaucoma prevention or progression.
Interpretation:
Dr. Welsbie described both approaches as under investigation. He does not routinely recommend either; he characterized the risk-benefit evidence for GLP-1 receptor agonists as more favorable than that for nicotinamide.
Limitations:
- Early nicotinamide studies relied on functional measures subject to substantial variability.
- The nicotinamide riboside trial did not show protection against progression.
- Observational GLP-1 studies cannot establish causality or demonstrate benefit for progression in established glaucoma.
- Randomized controlled trial evidence is needed for both approaches.
Conclusion:
The presentation emphasized unresolved questions about efficacy and safety and the need for randomized clinical trials.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.